Marizomib

Overview

Marizomib (Salinosporamide A) is a second-generation, irreversible, brain-penetrant, pan-proteasome inhibitor. Marizomib inhibits the CT-L (β5), CT-T-laspase-like (C-L, β1) and trypsin-like (T-L, β2) activities of the 20S proteasome (IC 50 =3.5, 28, and 430 nM, respectively).

Application

Products | Products > Disease Areas > Cancer | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Proteasome

Product Information

• Catalog No.: HY-10985
• CAS No.: 437742-34-2
• Molecular Formula: C15H20ClNO4
• Molecular Weight: 313.78
• Purity: 99.13%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
• Solubility: ≥ 2.08 mg/mL (6.63 mM); Clear solution
• Availability: In-stock

Source

Original product source